Company registration number 06593518 (England and Wales)
BEAGLE ORTHOPAEDIC LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
PAGES FOR FILING WITH REGISTRAR
BEAGLE ORTHOPAEDIC LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 10
BEAGLE ORTHOPAEDIC LIMITED
BALANCE SHEET
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
15,325
14,330
Tangible assets
4
1,279,882
1,313,392
Investments
5
1
1
1,295,208
1,327,723
Current assets
Stocks
7
529,056
549,770
Debtors
8
1,150,205
1,096,294
Cash at bank and in hand
38,007
261
1,717,268
1,646,325
Creditors: amounts falling due within one year
9
(2,374,149)
(2,130,169)
Net current liabilities
(656,881)
(483,844)
Total assets less current liabilities
638,327
843,879
Creditors: amounts falling due after more than one year
10
715,822
835,283
Capital and reserves
Called up share capital
11
1,000
1,000
Profit and loss reserves
(78,495)
7,596
Shareholders' funds
(77,495)
8,596
638,327
843,879
The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true
For the financial year ended 30 June 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
BEAGLE ORTHOPAEDIC LIMITED
BALANCE SHEET (CONTINUED)
- 2 -
The financial statements were approved by the board of directors and authorised for issue on 23 April 2026 and are signed on its behalf by:
L T Lloyd
Director
Company Registration No. 06593518
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 JUNE 2025
- 3 -
1
Accounting policies
Company information
Beagle Orthopaedic Limited is a private company limited by shares incorporated in England and Wales. The registered office is 6 Eghams Court, Boston Drive, Bourne End, Buckinghamshire, United Kingdom, SL8 5YS.
1.1
Accounting convention
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
1.3
Research and development expenditure
Research expenditure is written off against profits in the year in which it is incurred. Identifiable development expenditure is capitalised to the extent that the technical, commercial and financial feasibility can be demonstrated.
1.4
Intangible fixed assets other than goodwill
Intangible assets are initially measured at cost. After initial recognition, intangibles assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.
Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Patents & legal fees
- 7 Years
1.5
Tangible fixed assets
Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 4 -
Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:
Freehold land and buildings
- No depreciation
Plant and equipment
- 6 Years
Fixtures and fittings
- 5 Years
Furniture and office equipment
- 3 Years
Motor vehicles
- 4 Years
No depreciation is provided on freehold property, which is stated in the balance sheet at cost. The directors consider that as the remaining useful life of the property is more than 50 years and the estimated residual value is in excess of cost, the depreciation charge would be insignificant.
The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.
1.6
Fixed asset investments
Interests in subsidiaries, are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.
A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.
1.7
Stocks
Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.
At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.
1.8
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.9
Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.
Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.
Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 5 -
Basic financial assets
Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.
Classification of financial liabilities
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.
Basic financial liabilities
Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.
Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.
1.10
Equity instruments
Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.
1.11
Taxation
The tax expense represents the sum of the tax currently payable and deferred tax.
Current tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
1
Accounting policies
(Continued)
- 6 -
Deferred tax
Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.
The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.
1.12
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
1.13
Leases
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.
Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.
Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.
1.14
Foreign exchange
Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.
1.15
The company discounts its trade debts. The accounting policy is to include trade debtors discounted with recourse within trade debtors due within one year and the returnable element of the proceeds within current liabilities. Discounting charges and interest are charged to profit and loss account when paid. Bad debts are borne by the company and are charged to the income statement when incurred.
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 7 -
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2025
2024
Number
Number
Total
73
76
3
Intangible fixed assets
Other
£
Cost
At 1 July 2024
81,757
Additions
5,510
At 30 June 2025
87,267
Amortisation and impairment
At 1 July 2024
67,427
Amortisation charged for the year
4,515
At 30 June 2025
71,942
Carrying amount
At 30 June 2025
15,325
At 30 June 2024
14,330
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 8 -
4
Tangible fixed assets
Freehold land and buildings
Plant and equipment
Fixtures and fittings
Furniture and office equipment
Motor vehicles
Total
£
£
£
£
£
£
Cost
At 1 July 2024
803,439
560,443
259,426
121,633
128,756
1,873,697
Additions
16,393
52,259
3,618
3,472
3,462
79,204
At 30 June 2025
819,832
612,702
263,044
125,105
132,218
1,952,901
Depreciation and impairment
At 1 July 2024
207,141
228,407
113,851
10,906
560,305
Depreciation charged in the year
73,717
8,056
4,757
26,184
112,714
At 30 June 2025
280,858
236,463
118,608
37,090
673,019
Carrying amount
At 30 June 2025
819,832
331,844
26,581
6,497
95,128
1,279,882
At 30 June 2024
803,439
353,302
31,019
7,782
117,850
1,313,392
The carrying value of land and buildings comprises freehold property of £625,362 and improvements to property of £194,470.
5
Fixed asset investments
2025
2024
£
£
Other investments other than loans
1
1
Fixed asset investments revalued
The investment in Ortho Fabrication Limited has been valued by the directors at £1 as the company has ceased trading.
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 9 -
6
Secured Debts
The following secured debts are included within creditors:
2025
2024
£
£
Invoice discounting agent
558,481
596,269
Commercial mortgage
119,269
147,858
Coronavirus Business Interruption Scheme loan
125,001
185,001
802,751
929,128
A maximum of £58,333 (2024: £58,333) of the invoice discounting finance is secured by personal guarantees from two of the directors of the company.
Secured debts are covered by way of fixed and floating charge(s) with a negative pledge, the commercial mortgage is secured over the property to which it relates.
7
Stocks
2025
2024
£
£
Stocks
529,056
549,770
8
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
815,440
775,722
Corporation tax recoverable
17,812
Other debtors
85,503
93,909
900,943
887,443
2025
2024
Amounts falling due after more than one year:
£
£
Deferred tax asset
249,262
208,851
Total debtors
1,150,205
1,096,294
BEAGLE ORTHOPAEDIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 JUNE 2025
- 10 -
9
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans and overdrafts
89,923
92,906
Trade creditors
755,020
899,308
Taxation and social security
749,605
278,035
Other creditors
779,601
859,920
2,374,149
2,130,169
10
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
164,347
242,936
Obligations under finance leases
142,048
242,725
Other creditors
409,426
349,622
715,821
835,283
11
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
B Ordinary of £1 each
800
800
800
800
C Ordinary of £1 each
100
100
100
100
D Ordinary of £1 each
100
100
100
100
1,000
1,000
1,000
1,000
12
Operating lease commitments
Lessee
At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:
2025
2024
£
£
22,143
85,000
13
Directors' transactions
During the year ended 30 June 2025 the company received an interest free loan from three of its Directors.
At the balance sheet date £415,428 (2024: £375,623) was outstanding and included within creditors.
2025-06-302024-07-01falsefalsefalse23 April 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityL T LloydK P DavisMs K HalsallM R SalvageK F BaileyM R Salvage065935182024-07-012025-06-30065935182025-06-30065935182024-06-3006593518core:IntangibleAssetsOtherThanGoodwill2025-06-3006593518core:IntangibleAssetsOtherThanGoodwill2024-06-3006593518core:LandBuildingscore:OwnedOrFreeholdAssets2025-06-3006593518core:PlantMachinery2025-06-3006593518core:FurnitureFittings2025-06-3006593518core:ComputerEquipment2025-06-3006593518core:MotorVehicles2025-06-3006593518core:LandBuildingscore:OwnedOrFreeholdAssets2024-06-3006593518core:PlantMachinery2024-06-3006593518core:FurnitureFittings2024-06-3006593518core:ComputerEquipment2024-06-3006593518core:MotorVehicles2024-06-3006593518core:CurrentInventories2025-06-3006593518core:CurrentInventories2024-06-3006593518core:CurrentFinancialInstrumentscore:WithinOneYear2025-06-3006593518core:CurrentFinancialInstrumentscore:WithinOneYear2024-06-3006593518core:CurrentFinancialInstruments2025-06-3006593518core:CurrentFinancialInstruments2024-06-3006593518core:Non-currentFinancialInstruments2025-06-3006593518core:Non-currentFinancialInstruments2024-06-3006593518core:ShareCapital2025-06-3006593518core:ShareCapital2024-06-3006593518core:RetainedEarningsAccumulatedLosses2025-06-3006593518core:ShareCapitalOrdinaryShareClass22025-06-3006593518core:ShareCapitalOrdinaryShareClass22024-06-3006593518core:ShareCapitalOrdinaryShareClass32025-06-3006593518core:ShareCapitalOrdinaryShareClass32024-06-3006593518core:ShareCapitalOrdinaryShareClass42025-06-3006593518core:ShareCapitalOrdinaryShareClass42024-06-3006593518core:ShareCapitalOrdinaryShares2025-06-3006593518core:ShareCapitalOrdinaryShares2024-06-3006593518bus:Director12024-07-012025-06-3006593518core:IntangibleAssetsOtherThanGoodwill2024-07-012025-06-3006593518core:PatentsTrademarksLicencesConcessionsSimilar2024-07-012025-06-3006593518core:LandBuildingscore:OwnedOrFreeholdAssets2024-07-012025-06-3006593518core:PlantMachinery2024-07-012025-06-3006593518core:FurnitureFittings2024-07-012025-06-3006593518core:ComputerEquipment2024-07-012025-06-3006593518core:MotorVehicles2024-07-012025-06-30065935182023-07-012024-06-3006593518core:IntangibleAssetsOtherThanGoodwill2024-06-3006593518core:LandBuildingscore:OwnedOrFreeholdAssets2024-06-3006593518core:PlantMachinery2024-06-3006593518core:FurnitureFittings2024-06-3006593518core:ComputerEquipment2024-06-3006593518core:MotorVehicles2024-06-30065935182024-06-3006593518core:AfterOneYear2025-06-3006593518core:AfterOneYear2024-06-3006593518core:Non-currentFinancialInstrumentscore:AfterOneYear2025-06-3006593518core:Non-currentFinancialInstrumentscore:AfterOneYear2024-06-3006593518bus:OrdinaryShareClass22024-07-012025-06-3006593518bus:OrdinaryShareClass32024-07-012025-06-3006593518bus:OrdinaryShareClass42024-07-012025-06-3006593518bus:OrdinaryShareClass22025-06-3006593518bus:OrdinaryShareClass22024-06-3006593518bus:OrdinaryShareClass32025-06-3006593518bus:OrdinaryShareClass32024-06-3006593518bus:OrdinaryShareClass42025-06-3006593518bus:OrdinaryShareClass42024-06-3006593518bus:AllOrdinaryShares2025-06-3006593518bus:AllOrdinaryShares2024-06-3006593518bus:PrivateLimitedCompanyLtd2024-07-012025-06-3006593518bus:SmallCompaniesRegimeForAccounts2024-07-012025-06-3006593518bus:FRS1022024-07-012025-06-3006593518bus:AuditExemptWithAccountantsReport2024-07-012025-06-3006593518bus:Director22024-07-012025-06-3006593518bus:Director32024-07-012025-06-3006593518bus:Director42024-07-012025-06-3006593518bus:Director52024-07-012025-06-3006593518bus:CompanySecretary12024-07-012025-06-3006593518bus:FullAccounts2024-07-012025-06-30xbrli:purexbrli:sharesiso4217:GBP